ARTICLE | Clinical News
GMI-1271: Phase I started
September 26, 2016 7:00 AM UTC
GlycoMimetics began an open-label, Irish Phase I trial to evaluate 4 dose levels of IV GMI-1271 plus Velcade bortezomib in about 24 patients who had an inadequate response to Velcade. ...